Bain Capital

Bain Capital

About Bain Capital

Simplify's Rating
Why Bain Capital is rated
C
Rated C on Competitive Edge
Rated B on Growth Potential
Rated D+ on Rating Differentiation

Industries

Venture Capital

Social Impact

Financial Services

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$11.5B

Headquarters

Boston, Massachusetts

Founded

1984

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Bain Capital's acquisition of Apleona increases its market share in European facility management.
  • The strategic investment in SelectQuote positions Bain Capital in the growing Medicare insurance market.
  • Bain Capital's sale of assets to Greystar highlights its focus on the flexible living market.

What critics are saying

  • Potential overextension in pharmaceuticals may strain Bain Capital's resources and management focus.
  • Regulatory hurdles could delay the Italmatch Chemicals acquisition, impacting growth strategy.
  • The acquisition of Apleona may face integration challenges, affecting operational efficiency.

What makes Bain Capital unique

  • Bain Capital's acquisition of Mitsubishi Tanabe aligns with Japan's relaxed drug approval regulations.
  • The acquisition of Italmatch Chemicals leverages Bain Capital's expertise in the chemical sector.
  • Bain Capital's investment in Milacron enhances its portfolio in the plastic processing solutions sector.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$11488.9M

Above

Industry Average

Funded Over

0 Rounds

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

SafeBond Medical
Feb 16th, 2025
Bain Capital Acquires Mitsubishi Tanabe for $3.3B

Bain Capital has acquired Tanabe Mitsubishi Pharmaceutical from Mitsubishi Chemical Group for $3.3 billion. The deal, expected to close in Q3 2025, will make Tanabe an independent company. Bain Capital aims to introduce innovative drugs to Japan and leverage Tanabe's platform for commercial collaborations. This acquisition aligns with Japan's relaxed drug approval regulations, offering growth opportunities in the Japanese life sciences industry.

Bain Capital
Feb 14th, 2025
Bain Capital Acquires Italmatch Chemicals

Bain Capital Private Equity has signed a definitive agreement to acquire Italmatch Chemicals from Ardian. Italmatch, founded in 1997, is a global specialty chemical additive manufacturer with 2017 sales of approximately €400 million. The company operates 17 manufacturing sites globally. The transaction, subject to regulatory approval, marks a new growth phase for Italmatch, leveraging Bain Capital's expertise in the chemical sector.

PE Insights
Feb 14th, 2025
Bain Capital finalises €4bn acquisition of Apleona from PAI Partners | Private Equity Insights

Bain Capital finalises €4bn acquisition of Apleona from PAI Partners Bain Capital completed the acquisition of German facility management company Apleona from PAI Partners in a deal valued at approximately €4bn ($4.2bn). The transaction marks one of the most significant private equity deals in the European facility management sector in recent years. Apleona, formerly part […]

Business Wire
Feb 11th, 2025
SelectQuote Announces $350 Million Strategic Investment from Bain Capital, Morgan Stanley Private Credit and Newlight Partners

SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare service

Finsmes
Feb 10th, 2025
Bain Capital To Buy Mitsubishi Tanabe Pharma Corporation

Bain Capital, a Boston, MA-based global private investment firm, announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation, an Osaka, Japan-based company developing drugs, in a carve-out transaction from Mitsubishi Chemical Group Corporation.The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (3.3 billion USD). The deal is expected to close in the third quarter of 2025 and is subject to customary closing conditions, regulatory clearance and shareholder approvals.As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities, enhanced RD productivity, commercialization and strategic acquisitions.Founded in 1678, Tanabe Pharma focuses on several priority therapeutic areas, including immunology inflammation, vaccines, central nervous system (CNS), diabetes and metabolic disease. It employs over 5,000 people globally.Founded in 1984, Bain Capital is a private investment firms committed to creating impact for its investors, teams, businesses, and the communities. Its global platform invests across five focus areas: Private Equity, Growth Venture, Capital Solutions, Credit Capital Markets, and Real Assets. FinSMEs 10/02/2025

Recently Posted Jobs

Sign up to get curated job recommendations

Bain Capital is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Bain Capital's jobs every 8 hours, so check again soon! Browse all jobs →